Sun Pharma Advanced Research Company Limited (NSE: SPARC)

Market Cap	73.25B
Revenue (ttm)	684.05M
Net Income (ttm)	-3.88B
Shares Out	324.52M
EPS (ttm)	-11.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,212,551
Open	228.50
Previous Close	224.54
Day's Range	224.09 - 232.27
52-Week Range	196.10 - 472.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2024

About SPARC

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 409
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SPARC

Financial Performance

In 2023, SPARC's revenue was 755.45 million, a decrease of -68.36% compared to the previous year's 2.39 billion. Losses were -3.87 billion, 74.0% more than in 2022.